Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Free Cash Flow (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Free Cash Flow for 14 consecutive years, with $38.4 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 35.94% to $38.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $141.8 million through Dec 2025, down 27.71% year-over-year, with the annual reading at $141.8 million for FY2025, 27.71% down from the prior year.
  • Free Cash Flow hit $38.4 million in Q4 2025 for Corcept Therapeutics, down from $54.5 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $71.7 million in Q3 2024 to a low of $5.0 million in Q1 2025.
  • Historically, Free Cash Flow has averaged $37.6 million across 5 years, with a median of $39.6 million in 2024.
  • Biggest five-year swings in Free Cash Flow: plummeted 83.42% in 2023 and later skyrocketed 984.05% in 2024.
  • Year by year, Free Cash Flow stood at $49.4 million in 2021, then plummeted by 32.42% to $33.4 million in 2022, then tumbled by 83.42% to $5.5 million in 2023, then surged by 984.05% to $59.9 million in 2024, then plummeted by 35.94% to $38.4 million in 2025.
  • Business Quant data shows Free Cash Flow for CORT at $38.4 million in Q4 2025, $54.5 million in Q3 2025, and $43.9 million in Q2 2025.